Among these, several studies have focused on their possible applicability in clinical practice: proteins such as mesothelin [104,105,106,107,108,109,110], osteopontin [105,111,112], Fibuline-3 (FBLN3) [109,110,113], High-mobility group box 1 (HMGB1) [114,115,116], CD138 [117], angiogenic factors [118,119], microRNAs [120,121], circulating tumour DNA (ctDNA) [122,123,124], circulating tumour cells (CTCs) [125,126], exosomes [127]. This evidence concerns the gene MSLN and neoplasm.